Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237977 | 0.84 | MAPT (0.34) | MAPTHTTKDM1AALDH1A1RAB9A | |
| SCHEMBL13058516 | 0.82 | MAPT (0.32) | MAPTALDH1A1RAB9APTGS1PTGS2 | |
| SCHEMBL10237934 | 0.81 | RAB9A (0.40) | MAPTALDH1A1RAB9AACHE | |
| SCHEMBL10237898 | 0.80 | KDM4E (0.41) | MAPTALDH1A1RAB9A | |
| SCHEMBL10238058 | 0.79 | ALDH1A1 (0.37) | MAPTALDH1A1RAB9AACHEPDE4D | |
| SCHEMBL10237915 | 0.78 | SLC6A3 (0.39) | MAPTALDH1A1RAB9AACHEPDE4B | |
| SCHEMBL10237932 | 0.78 | PIK3CA (0.37) | MAPTALDH1A1RAB9AACHE | |
| SCHEMBL10237919 | 0.78 | RAB9A (0.38) | MAPTALDH1A1RAB9A | |
| SCHEMBL10238017 | 0.78 | ALDH1A1 (0.41) | MAPTALDH1A1RAB9AACHE | |
| SCHEMBL10237917 | 0.77 | DHODH (0.35) | MAPTHTTRAB9AACHEPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176222-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2014-11-05 | — | — | EP | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| WO-2009015877-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040826-A1 | NOVEL HERBICIDES | DDT, HDHD5, DDC | MAPT 3907/4885HTT 373/4885KDM1A 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.